Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 27, 2019Molecular Therapy — Methods & Clinical DevelopmentOpen Access

Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAnna MajowiczSpark Therapeutics (United States)BNBart NijmeijerAstraZeneca (United Kingdom)MLMargit H. LampenUniQure (Netherlands)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Majowicz et al. (2019) studied this question.

synapsesocial.com/papers/6a01c5558d267ec217d8bd6dhttps://doi.org/10.1016/j.omtm.2019.05.009
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Strategy to detect pre-existing immunity to AAV gene therapy2017 · 101 citations
  2. 2Adeno-Associated Virus (AAV) Type 5 Rep Protein Cleaves a Unique Terminal Resolution Site Compared with Other AAV Serotypes1999 · 78 citations
  3. 3New Recombinant Serotypes of AAV Vectors2005 · 489 citations
  4. 4Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques2002 · 164 citations
  5. 5Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents2011 · 348 citations